Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles.
about
Nanotechnology-based inhalation treatments for lung cancer: state of the artImaging the paediatric lung: what does nanotechnology have to offer?In vivo biocompatibility, clearance, and biodistribution of albumin vehicles for pulmonary drug deliveryPreclinical lymphatic imaging.Low cytotoxicity of solid lipid nanoparticles in in vitro and ex vivo lung models.Nanomedicine in pulmonary deliveryFormulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers.Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles.Antitubercular inhaled therapy: opportunities, progress and challenges.The nanoscale in pulmonary delivery. Part 1: deposition, fate, toxicology and effects.The nanoscale in pulmonary delivery. Part 2: formulation platforms.Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives.Advanced drug delivery to the lymphatic system: lipid-based nanoformulations.Deep pulmonary lymphatics in immature lungs.Nanocarriers for pulmonary administration of peptides and therapeutic proteins.Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery.Toxico-/biokinetics of nanomaterials.Lipid-based carriers: manufacturing and applications for pulmonary route.Passive lung-targeted drug delivery systems via intravenous administration.Lymphatic system: a prospective area for advanced targeting of particulate drug carriers.Stabilization of food dispersions by enzymes.Nanomaterials for enhanced immunity as an innovative paradigm in nanomedicine.The function and performance of aqueous aerosol devices for inhalation therapy.(89)Zr-labeled anti-endoglin antibody-targeted gold nanoparticles for imaging cancer: implications for future cancer therapy.Nanoparticle transport and delivery in a heterogeneous pulmonary vasculature.Fabrication and evaluation of lipid nanoparticulates for ocular delivery of a COX-2 inhibitor.Biodistribution of amikacin solid lipid nanoparticles after pulmonary delivery.Evaluation of biocompatible stabilised gelled soya bean oil nanoparticles as new hydrophobic reservoirs.Iodinated NanoClusters as an inhaled computed tomography contrast agent for lung visualization.Microparticles containing erlotinib-loaded solid lipid nanoparticles for treatment of non-small cell lung cancer.Immunotoxicological impact of occupational and environmental nanoparticles exposure: The influence of physical, chemical, and combined characteristics of the particles.Nanoparticle Vaccines Adopting Virus-like Features for Enhanced Immune PotentiationLymphatic uptake of lipid nanoparticles following endotracheal administrationDistribution of effervescent inhalable nanoparticles after pulmonary delivery: anin vivostudy
P2860
Q26774177-442A0C42-B33C-4E6A-8890-5DEBB4C15AC5Q26996739-4D0DCE8B-569D-4028-B586-B53F119F0506Q28396006-FEA51ACE-3026-4974-8B70-98AB5C38842EQ30465292-9A4B1A30-C1F8-45B2-AE79-D8433A316577Q33475063-61808251-E0D8-4938-99F7-7A8F3744A941Q33572981-59478E6C-FE7C-4635-BBE8-88F5B3D3FC70Q33846935-5BF49FA9-026A-480C-A0A2-49B77CC281C5Q35188633-05EAF2DE-8B03-4C4E-A1D1-F6487026B63CQ36068001-01593810-03F2-4A13-B384-F8E78E6FB470Q36985892-68E32B67-DC98-4C0A-8063-A0EFFB8EAD0CQ36985898-12AC08D4-B25F-4F02-A541-AD9818B1E22BQ37004099-B44562E9-DB5B-493D-99BE-5105C706B381Q37066550-4B1D6705-036F-4C3E-BB13-307454332CACQ37372417-3A50273C-F0CC-4FD3-B0AB-3440A6049F04Q37823598-08522649-5EF9-40D4-83DB-3C639B71D6A8Q37996097-56A854ED-168F-4549-AE7A-474EC3B3A488Q38009230-CABA177A-FBBF-4A77-B2B6-DE37C37C16D3Q38020888-4B0E96C6-842F-4D9F-A074-8EC430A939E9Q38075609-C36C359C-FBC9-4442-A511-90052062C5BAQ38172276-BCF71BD7-E2ED-462C-94B6-E64BAEF3DF80Q38178530-6D1C60FD-262A-47C6-A915-B1BACAE21BD3Q38418305-B69EB549-2FB4-4CC3-A7F1-83EA935D6D51Q38803035-5A164915-1A25-42CA-8702-3CEA4166318AQ39023017-E8E5D697-68C0-4F4D-B930-F4B08AE84F64Q39173710-35D5AA42-2EF6-4476-A159-5C53413C7DB7Q39810160-57C949D4-E5C0-4436-8787-7392EF96D30BQ41994996-85630E7A-38C8-4412-BE23-3BCD3BDCEE4FQ42944298-581FF768-732A-4A35-8478-E2C3B912FBE5Q42958480-29D24B1B-7BEE-4803-B85F-58C638207B52Q48097759-7CF6123D-B3B7-40CE-A52E-E4C3B28580D1Q50316993-0D986204-02D4-49B0-9DF9-D0FE08CA2605Q56993652-3FD07996-02D7-4B46-BDC7-D0BBF3A1C603Q59166767-8F5FB278-1711-4B3B-95C3-D759BF433529Q59237431-C3629B1F-3FF2-439C-971B-3B6A340317AE
P2860
Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles.
@en
Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles.
@nl
type
label
Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles.
@en
Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles.
@nl
prefLabel
Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles.
@en
Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles.
@nl
P50
P1476
Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles.
@en
P2093
Ana C Santos
J J Pedroso de Lima
P304
P356
10.1080/1061186021000054933
P577
2002-12-01T00:00:00Z